Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each

Masahiro Sugawara, vice president of Japan Physicians Association The Japan Physicians Association has begun an investigator-initiated trial (IIT) to directly compare the efficacy and safety of DPP-4 inhibitors and SGLT2 inhibitors in patients with type 2 diabetes. The association will...read more